Category: organ transplant

  • Cell therapy biotech Quell adds $156M for alternative to organ transplant meds

    Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress comes as the field of Treg cell therapy research becomes increasingly competitive.

  • Quantifying spillover benefits in value assessment

    That is the title of a recent paper published in the Journal of Medical Economics with Syvart Dennan, Oliver Diaz, Kelly Birch, Jennifer Cai, Jennifer Sung, and Paula Machado. The subtitle is: A case study of increased graft survival on the US kidney transplant waitlist. The abstract is below: Aim: To quantify the wider impacts […]